


Have you noticed a Technetium-99m-MAA Shortage?

Why not choose QuiremScout® as your SIRT work-up instead?

We have a number of studies^{1,2,3} which demonstrate the advantages of QuiremScout® as a work-up when compared to ^{99m}Tc-MAA

- ✓ QuiremScout® is safe¹ in a clinical setting and provides a safe alternative for ^{99m}Tc-MAA for SIRT work-up
- ✓ QuiremScout® better predictor of lung shunting² when compared to ^{99m}Tc-MAA allows for more **accurate SIRT patient selection**
- ✓ QuiremScout® demonstrates a better prediction of intrahepatic distribution³ when compared to ^{99m}Tc-MAA which **may improve treatment planning** prior to SIRT



QuiremScout® is the first SIRT work-up product that utilizes the same technology as the therapeutic microspheres, which aims to optimize patient selection and advance treatment planning versus using ^{99m}Tc-MAA.

Please contact your local Terumo representative to discuss the opportunity to use QuiremScout® in your SIRT practise.

 QuiremScout®



1. Braat AJAT et al. Eur Radiol 2017
2. Elschot, M. et al. Eur. J. Nucl. Med. Mol. Imaging 2014
3. Smits, et al. Eur. J. Nucl. Med. Mol. Imaging 2019

**TERUMO**
INTERVENTIONAL
SYSTEMS

VISUALIZE SIRT SUCCESS FROM THE START WITH QUIREMSCOUT®

THE FIRST AND ONLY CE-MARKED
PRODUCT FOR SIRT WORK-UP



 **QuiremScout®**

 **QuiremSpheres®**

US 9496899.1 | 11/09 | 91E



www.terumo-europe.com

 **TERUMO**
INTERVENTIONAL
SYSTEMS

Not all products are available for sale in all countries. This information is provided only in respect to markets where these products are approved or cleared. Not all products are cleared or approved in the U.S.A. by the Food and Drug Administration. Please contact your Terumo local sales representative for more information.